Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Cibinqo on Dabigatran Pharmacokinetics in Healthy Participants
NCT03742336Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abrocitinib in atopic dermatitis (AD) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity at 36 hours and Maximum Plasma Concentration at 36 hours. Started Nov 2018; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03742336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742336.